BVS vs. UFPT, LMAT, ATEC, SINT, MDXG, ATRC, AORT, CATX, SILK, and KIDS
Should you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include UFP Technologies (UFPT), LeMaitre Vascular (LMAT), Alphatec (ATEC), Sintx Technologies (SINT), MiMedx Group (MDXG), AtriCure (ATRC), Artivion (AORT), Perspective Therapeutics (CATX), Silk Road Medical (SILK), and OrthoPediatrics (KIDS). These companies are all part of the "surgical & medical instruments" industry.
Bioventus (NYSE:BVS) and UFP Technologies (NASDAQ:UFPT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
UFP Technologies has a net margin of 11.75% compared to Bioventus' net margin of -4.14%. UFP Technologies' return on equity of 17.40% beat Bioventus' return on equity.
Bioventus has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, UFP Technologies has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
62.9% of Bioventus shares are owned by institutional investors. Comparatively, 87.3% of UFP Technologies shares are owned by institutional investors. 32.9% of Bioventus shares are owned by company insiders. Comparatively, 6.2% of UFP Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
UFP Technologies has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than UFP Technologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, UFP Technologies had 4 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for UFP Technologies and 1 mentions for Bioventus. UFP Technologies' average media sentiment score of 1.68 beat Bioventus' score of 0.10 indicating that UFP Technologies is being referred to more favorably in the news media.
UFP Technologies received 180 more outperform votes than Bioventus when rated by MarketBeat users. However, 60.47% of users gave Bioventus an outperform vote while only 59.03% of users gave UFP Technologies an outperform vote.
Bioventus currently has a consensus price target of $8.00, suggesting a potential upside of 19.58%. UFP Technologies has a consensus price target of $238.50, suggesting a potential downside of 8.40%. Given Bioventus' stronger consensus rating and higher probable upside, analysts clearly believe Bioventus is more favorable than UFP Technologies.
Summary
UFP Technologies beats Bioventus on 12 of the 18 factors compared between the two stocks.
Get Bioventus News Delivered to You Automatically
Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bioventus Competitors List
Related Companies and Tools
